Monitoring molecular changes in the management of myelodysplastic syndromes.
Nicolas DuployezClaude PreudhommePublished in: British journal of haematology (2024)
The ongoing or anticipated therapeutic advances as well as previous experience in other malignancies, including acute myeloid leukaemia, have made molecular monitoring a potential interesting tool for predicting outcomes and demonstrating treatment efficacy in patients with myelodysplastic syndromes (MDS). The important genetic heterogeneity in MDS has made challenging the establishment of recommendations. In this context, high-throughput/next-generation sequencing (NGS) has emerged as an attractive tool, especially in patients with high-risk diseases. However, its implementation in clinical practice still suffers from a lack of standardization in terms of sensitivity, bioinformatics and result interpretation. Data from literature, mostly gleaned from retrospective cohorts, show NGS monitoring when used appropriately could help clinicians to guide therapy, detect early relapse and predict disease evolution. Translating these observations into personalized patient management requires a prospective evaluation in clinical research and remains a major challenge for the next years.
Keyphrases
- clinical practice
- high throughput
- single cell
- systematic review
- healthcare
- case report
- dendritic cells
- electronic health record
- cross sectional
- type diabetes
- palliative care
- genome wide
- acute myeloid leukemia
- bone marrow
- risk assessment
- stem cells
- drug induced
- metabolic syndrome
- machine learning
- skeletal muscle
- combination therapy
- extracorporeal membrane oxygenation
- human health
- circulating tumor cells